Role of Natural Products in Drug Discovery

Lead Generation Approaches in Drug Discovery

Volumn , Issue , 2010, Pages 187-229

  Lachance, Hugo ^a,b   Wetzel, Stefan ^a,b   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Natural products source of modern medicinal chemistry compounds; Natural products as source of inspiration; Natural products in drug discovery

Indexed keywords

EID: 84860510662     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470584170.ch7     Document Type: Chapter

References (207)

1. Borchart, J. K. (2002). The beginnings of drug therapy: ancient mesopotamian medicine. Drug News Perspective, 15, 187-192.
2. Solecki, R. S. (1975). Shanidar IV, a Neanderthal flower burial in northern Iraq. Science New Series, 190(4217), 880-881.
3. Huxtable, R. J., Schwarz, S. K. W. (2001). The isolation of morphine-first principles in science and ethics. Molecular Interventions, 1, 189-191.
4. Lockemann, G. (1951). Friedrich Wilhelm Sertu rner, the discoverer of morphine. Journal of Chemical Education, 28, 277-279.
5. Hesse, M. (2000). Alkaloide. Wiley-VCH, Weinheim.
6. Kaufman, T. S., Ru veda, E. A. (2005). The quest for quinine: those whowon the battles and those who won the war. Angewandte Chemie-International Edition, 44, 854-885
7. Jeffrey, I., Seeman, J. I. (2007). The woodward-doering/rabe-kindler total synthesis of quinine: setting the record straight. Angewandte Chemie-International Edition, 46, 1378-1413.
8. Smith, A. C., Williams, R. W. (2008). Rabe rest in peace: confirmation of the rabe-kindler conversion of d-quinotoxine into quinine: experimental affirmation of the woodward-doering formal total synthesis of quinine. Angewandte Chemie- International Edition, 47, 1736-1740.
9. Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 21, 517-526.
10. Endo, A., Kuroda, M., Tsujita, Y. (1976). ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterolgenesis produced by Penicillium citrinium. Journal of Antibiotics, 29, 1346-1348.
11. Endo, A., Tsujita, Y., Kuroda, M., Tanzawa, K. (1997). Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. European Journal of Biochemistry, 77, 31-36.
12. Maggon, K. (2005). Best-selling human medicines 2002-2004. Drug Discovery Today, 10(11), 739-742.
13. Jeffreys, D. (2004). Aspirin, the remarkable story of a wonder drug. Bloomsbury Publishing, London.
14. Karenberg, A., Leitz, C. (2001). Headache in magical and medical papyri of Ancient Egypt. Cephalalgia, 21, 911-916.
15. Temkin, O. (1938). The papyrus Ebers by B. Ebbell. Isis, 28, 126-131.
16. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology, 231, 232-235.
17. Vane, J., Botting, R. (2003). The mechanism of action of aspirin. Trombosis Research, 110, 255-258.
18. Roth, G. J., Majerus, P. W. (1975). The mechanism of the effect of Aspirin on human platelets: I. Acetylation of a particulate fraction protein. Journal of Clinical Investigation, 56, 624-632.
19. Tohgi, H., Konno, S., Tamura, K., Kimura, B., Kawano, K. (1992). Effects of lowto- high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke, 23, 1400-1403.
20. Ligon, B. L. (2004). Penicillin: its discovery and early development. Seminars in Pediatric Infectious Diseases, 15, 52-57.
21. Fleming, A. (1929). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. Influenzae. British Journal of Experimental Pathology, 10, 3-13.
22. Chain, E., Florey, H. W., Gardner, A. D., Heatley, N. G., Jennings, M. A., Orr- Ewing, J., Sanders, A. G. (1940). Penicillin as a chemotherapeutic agent. The Lancet, 236(6104), 226-228.
23. Marshall, E. K. J. (1939). Baterial chemoterapy-the pharmacology of sulfanilamide. Physiologycal Reviews, 19, 240-269.
24. Birnbaum, J., Kahan, F. M., Kropp, M. A. H., Macdonald, L. S. (1985). Carbapenems, a new class of beta-lactam antibiotics discovery and development of imipenem/cilastatin. The American Journal of Medicine, 78(Suppl 6A), 3.
25. Kumagai, T., Tamai, S., Abe, T., Hikida, M. (2002). Current status of oral carbapenem development. Current Medicinal Chemistry-Anti-Infective Agents, 1, 1-14.
26. Mann, J. (2002). Natural products in cancer chemotherapy: past, present and future. Nature Reviews Cancer, 2, 143-148.
27. Miller, K., Neilan, B., Sze, D. M. Y. (2008). Development of Taxol and other endophyte produced anti-cancer agents. Recent Patents on Anti-Cancer Drug Discovery, 3, 14-19.
28. Heilmann, J. (2007). Wirkstoffe auf basis biologisch aktiver Naturstoffe. Chemie in Unserer Zeit, 41, 376-389.
29. Horwitz, S. B. (2004). Personal recollections on the early development of Taxol. Journal of Natural Products, 67, 136-138.
30. Cragg, G. M. (1998). Paclitaxel (Taxols): a success story with valuable lessons for natural product drug discovery and development. Medicinal Research Reviews, 18, 315-331.
31. Wall, M. E. (1998). Camptothecin and Taxol: discovery to clinic. Medicinal Research Reviews, 18, 299-314.
32. Cragg, G. M., Newman, D. J. (2004). A tale of two tumor targets: topoisomerase i and tubulin. The wall and wani contribution to cancer chemotherapy. Journal of Natural Products, 67, 232-244.
33. Oberlies, N. H., Kroll, D. J. (2004). Camptothecin and Taxol: historic achievements in natural products research. Journal of Natural Products, 67, 129-135.
34. Wilson, R. M., Danishefsky, S. J. (2006). Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. Journal of Organic Chemistry, 71(22), 8329-8351.
35. Johnson, I. S., Armstrong, J. G., Gorman, M., Bunett, J. J. P. (1963). The vinca alkaloids: a new class of oncolytic agents. Cancer Research, 23, 1390-1427.
36. Giddinga, C. E. M., Kellieb, S. J., Kampsa, W. A., de Graafa, S. S. N. (1999). Vincristine revisited. Critical Reviews in Oncology Hematology, 29, 267-287.
37. Saklani, A., Kutty, S. K. (2008). Plant-derived compounds in clinical trials. Drug Discovery Today, 13, 161-171.
38. Kingston, D. G. I., Newman, D. J. (2005). The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries. Current Opinion in Drug Discovery and Development, 8(2), 207-227.
39. Newman, D. J., Cragg, G. M. (2006). Natural products from marine invertebrates and microbes as modulators of antitumor targets. Current Drug Targets, 7(3), 279-304.
40. Newman, D. J., Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70(3), 461-477.
41. Newman, D. J., Cragg, G. M. (2004). Marine natural products and related compounds in clinical and advance preclinical trials. Journal of Natural Products, 67, 1216-1238
42. Ojima, I. (2008). Modern natural products chemistry and drug discovery. Journal of Medicinal Chemistry, 51, 2587-2588.
43. Banerjee, S., Wang, Z., Mohammad, M., Sarkar, F. H., Mohammad, R. M. (2008). Efficacy of selected natural products as therapeutic agents against cancer. Journal of Natural Products, 71, 492-496.
44. Butler, M. S. (2008). Natural products to drugs: natural product-derived compounds in clinical trials. Natural Product Reports, 25, 475-516.
45. Molinski, T. F., Dalisay, D. S., Lievens, S. L., Saludes, J. P. (2009). Drug development from marine natural products. Nature Reviews Drug Discovery, 8(1), 69-85.
46. Newman, D. J., Cragg, G. M., Snader, K. M. (2003). Natural products as sources of new drugs over the period 1981-2002. Journal of Natural Products, 66(7), 1022-1037.
47. Nicolaou, K. C., Snyder, S. A. (2004). The essence of total synthesis. Proceedings of the National Academy of Sciences of the United States of America, 101(33), 11929-11936.
48. Heilmann, J. (2007). Active substances from biologically active natural products. Chemie in Unserer Zeit, 41(5), 376-389.
49. Bhushan, P., Manish, G. (2007). Ethnopharmacology approaches for botanical immunomodulators and chemoprotectants in cancer therapy. Annals of Traditional Chinese Medicine, 3, 255-284.
50. Das, K., Dang, R., Bhaskaran, S., Roopashree, T. S. (2008). Recent advances in medicinal plants in diabetes treatment. Recent Progress in Medicinal Plants, 19, 151-191.
51. Mali, R. G., Mahajan, S. G., Mehta, A. A. (2007). Rakta kanchan (Bauhinia variegata): chemistry, traditional and medicinal uses-a review. Pharmacognosy Reviews, 1(2), 314-319.
52. Sangwan, R. S., Chaurasiya, N. D., Lal, P., Misra, L., Tuli, R., Sangwan, N. S. (2008). Withanolide A is inherently de novo biosynthesized in roots of the medicinal plant Ashwagandha (Withania somnifera). Physiologia Plantarum, 133(2), 278-287.
53. Deocaris, C. C., Widodo, N., Wadhwa, R., Kaul, S. C. (2008). Merger of ayurveda and tissue culture-based functional genomics: inspirations from systems biology. Journal of Translational Medicine, 6.
54. Imakura, Y., Hachiya, K., Ikemoto, T., Kobayashi, S., Yamashita, S., Sakakibara, J., Smith, F. T., Lee, K. H. (1990). Antimalarial, artemisinin analogs: synthesis of 2, 3-deethano-12-deoxoartemisinin-related compounds. Heterocycles, 31(12), 2125-2129.
55. Imakura, Y., Hachiya, K., Ikemoto, T., Yamashita, S., Kihara, M., Kobayashi, S., Shingu, T., Milhous, W. K., Lee, K. H. (1990). Acid degradation products of qinghaosu and their structure-activity relationships. Heterocycles, 31(6), 1011-1016.
56. Imakura, Y., Yokoi, T., Yamagishi, T., Koyama, J., Hu, H., McPhail, D. R., McPhail, A. T., Lee, K. (1988). Synthesis of deethanoqinghaosu, a novel analog of the antimalarial qinghaosu. Journal of the Chemical Society, Chemical Communications, 5, 372-374.
57. White, N. J. (2008). Qinghaosu (Artemisinin): the price of success. Science, 320 (5874), 330-334.
58. Liu, G. T. (1983). From the study of Fructus schizandrae to the discovery of biphenyl dimethyl-dicarboxylate. Yao xue xue bao = Acta pharmaceutica Sinica, 18(9), 714-720.
59. McChesney, J. D., Venkataraman, S. K., Henri, J. T. (2007). Plant natural products: back to the future or into extinction? Phytochemistry, 68(14), 2015-2022.
60. Haefner, B. (2003). Drugs from the deep: marine natural products as drug candidates. Drug Discovery Today, 8(12), 536-544.
61. Hamann, M. T., Hill, R., Roggo, S. (2007). Marine natural products. Key advances to the practical application of this resource in drug development. Chimia, 61(6), 313-321.
62. Skropeta, D. (2008). Deep-sea natural products. Natural Product Reports, 25(6), 1131-1166.
63. Henkel, T., Brunne, R. M., Muller, H., Reichel, F. (1999). Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angewandte Chemie, International Edition, 38(5), 643-647.
64. Crews, P., Gerwick, W. H., Schmitz, F. J., France, D., Bair, K. W., Wright, A. E., Hallock, Y. (2003). Molecular approaches to discover marine natural product anticancer leads-An update from a drug discovery group collaboration. Pharmaceutical Biology, 41, 39-52.
65. de Fatima, A., Modolo, L. V., Sanches, A. C. C., Porto, R. R. (2008). Wound healing agents: the role of natural and non-natural products in drug development. Mini-Reviews in Medicinal Chemistry, 8(9), 879-888.
66. Gordaliza, M. (2007). Natural products as leads to anticancer drugs. Clinical and Translational Oncology, 9(12), 767-776.
67. Lee, K. H. (2000). Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutrition, 3(4A), 515-522.
68. Mehta, G., Singh, V. (2002). Hybrid systems through natural product leads: an approach towards new molecular entities. Chemical Society Reviews, 31(6), 324-334.
69. Newman, D. J. (2008). Natural products as leads to potential drugs: an old process or the new hope for drug discovery? Journal of Medicinal Chemistry, 51(9), 2589- 2599.
70. Peric-Concha, N., Long, P. F. (2003). Mining the microbial metabolome: a new frontier for natural product lead discovery. Drug Discovery Today, 8(23), 1078-1084.
71. Potterat, O. (2006). Targeted approaches in natural product lead discovery. Chimia, 60(1-2), 19-22.
72. Rishton, G. M. (2008). Natural products as a robust source of new drugs and drug leads: past successes and present day issues. American Journal of Cardiology, 101 (10A), 43D-49D.
73. Liu, Y.-Q., Yang, L., Tian, X. (2007). Podophyllotoxin: current perspectives. Current Bioactive Compounds, 3(1), 37-66.
74. King, L. S., Sullivan, M. (1946). Similarity of the effect of podophyllin and colchicine and their use in the treatment of condylomata acuminata. Science, 104, 244-245
75. Long, B. H., and Brattain, M. G. The activity of etoposide (VP16-213) and teniposide (VM26) against human lung tumor cells in vitro: cytotoxicity and DNA breakage. In: B. F. Issell. F. Muggia. and S. K. Carter (eds.). Etoposide (VP 16-213): Current Status and New Developments, pp. 63-86. New York: Academic Press. 1984.
76. Long, B. H., Musial, S. T., Brattain, M. G. (1984). Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry, 23(6), 1183-1188.
77. Minocha, A., Long, B. H. (1984). Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochemical and Biophysical Research Communications, 122(1), 165-170.
78. Munro, M. H. G., Blunt, J. W., Dumdei, E. J., Hickford, S. J. H., Lill, R. E., Li, S., Battershill, C. N., Duckworth, A. R. (1999). The discovery and development of marine compounds with pharmaceutical potential. Journal of Biotechnology, 70(1-3), 15-25.
79. Zhu, X. K., Guan, J., Tachibana, Y., Bastow, K. F., Cho, S. J., Cheng, H. H., Cheng, Y. C., Gurwith, M., Lee, K. H. (1999). Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4u-Odemethyl- podophyllotoxin and related compounds with improved pharmacological profiles. Journal of Medicinal Chemistry, 42(13), 2441-2446.
80. Dabydeen, D. A., Burnett, J. C., Bai, R., Verdier-Pinard, P., Hickford, S. J. H., Pettit, G. R., Blunt, J. W., Munro, M. H. G., Gussio, R., Hamel, E. (2006). Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Molecular Pharmacology, 70(6), 1866-1875.
81. Newman, S. (2007). Drug evaluation: eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Current Opinion in Investigational Drugs, 8(12), 1057-1066.
82. Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B. A., Jordan, M. A. (2008). Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Molecular Cancer Therapeutics, 7(7), 2003-2011.
83. Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., Wilson, L. (2005). The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Molecular Cancer Therapeutics, 4(7), 1086-1095.
84. Hirata, Y., Uemura, D. (1986). Halichondrins-antitumor polyether macrolides from a marine sponge. Pure and Applied Chemistry, 58(5), 701-710.
85. Uemura, D., Takahashi, K., Yamamoto, T., Katayama, C., Tanaka, J., Okumura, Y., Hirata, Y. (1985). Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. Journal of the American Chemical Society, 107(16), 4796-4798.
86. Martinez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural environments. Science, 321(5887), 365-367.
87. Singh, M. P., Greenstein, M. (2000). Antibacterial leads from microbial natural products discovery. Current Opinion in Drug Discovery and Development, 3(2), 167-176.
88. Wright, G. D., Sutherland, A. D. (2007). New strategies for combating multidrugresistant bacteria. Trends in Molecular Medicine, 13(6), 260-267.
89. Gordon, J. J., Kelly, B. K., Miller, G. A. (1962). Actinonin: an antibiotic substance produced by an actinomycete. Nature, 195, 701-702.
90. Attwood, M. M. (1969). Mode of action of actinonin. Journal of General Microbiology, 55(2), 209-216.
91. Anderson, N. H., Ollis, W. D., Thorpe, J. E., Ward, A. D. (1974). Total synthesis of the antibiotic, actinonin. Journal of the Chemical Society, Chemical Communications, 11, 420-421.
92. Anderson, N. H., Ollis, W. D., Thorpe, J. E., Ward, A. D. (1975). Antibiotic actinonin. II. Total synthesis of actinonin and structural analogs by the isomaleimide method. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 9, 825-830.
93. Broughton, B. J., Warren, P. J., Wooldridge, K. R. H., Wright, D. E., Ollis, W. D., Wood, R. J. (1975). Antibiotic actinonin. IV. Synthesis of structural analogs of actinonin by the mixed anhydride method. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 9, 842-846.
94. Devlin, J. P., Ollis, W. D. Thorpe, J. E. (1975). Antibiotic actinonin. V. Synthesis of structural analogs of actinonin by the anhydride-ester method. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 9, 846-848.
95. Devlin, J. P., Ollis, W. D., Thorpe, J. E., Wood, R. J., Broughton, B. J., Warren, P. J., Wooldridge, K. R. H., Wright, D. E. (1975). Antibiotic actinonin. III. Synthesis of structural analogs of actinonin by the anhydride-imide method. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 9, 830-841.
96. Broughton, B. J., Chaplen, P., Freeman, W. A., Warren, P. J., Wooldridge, K. R. H., Wright, D. E. (1975). Antibiotic actinonin. VIII. Structure-activity relations in the actinonin series. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 9, 857-860.
97. Umezawa, H., Aoyagi, T., Tanaka, T., Suda, H., Okuyama, A., Naganawa, H., Hamada, M., Takeuchi, T. (1985). Production of actinonin, an inhibitor of aminopeptidase M, by actinomycetes. Journal of Antibiotics, 38(11), 1629-1630.
98. Chen, D. Z., Patel, D. V., Hackbarth, C. J., Wang, W., Dreyer, G., Young, D. C., Margolis, P. S., Wu, C., Ni, Z.-J., Trias, J., White, R. J., Yuan, Z. (2000). Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry, 39(6), 1256-1262.
99. CRC Dictionary of Natural Products, CRC Press, 78, 318 structural entries, June 1996; http://www.crcpress.com/
100. Bioactive Natural Product Database, Szenzor Management Consulting Company, Budapest, (Hungary) (by Berdy), 29, 432 entries of natural products with described biological activity (status: July 96).
101. ACD: Available Chemicals Directory, Version 93.2, from Molecular Design Ltd. Information Systems Inc., San Leandro, CA, USA, 182 822 entries.
102. Lee, M. L., Schneider, G. (2001). Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural REFERENCES 221 product-based combinatorial libraries. Journal of Combinatorial Chemistry, 3(3), 284-289.
103. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1-3), 3-25.
104. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26.
105. Feher, M., Schmidt, J. M. (2003). Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. Journal of Chemical Information and Computer Sciences, 43(1), 218-227.
106. Grabowski, K., Schneider, G. (2007). Properties and architecture of drugs and natural products revisited. Current Chemical Biology, 1(1), 115-127.
107. Ertl, P., Schuffenhauer, A. (2007). Cheminformatics analysis of natural products. Lessons from nature inspiring the design of new drugs. In: Petersen, F., Amstutz, R., eds., Natural products as drugs. Birkhaeuser Verlag, Basel, CH.
108. Wessjohann, L. A., Ruijter, E., Garcia-Rivera, D., Brandt, W. (2005). What can a chemist learn from nature's macrocycles? A brief, conceptual view. Molecular Diversity, 9(1-3), 171-186.
109. Kirkpatrick, P., Ellis, C. (2004). Chemical space. Nature, 432(7019), 823.
110. Bohacek, R. S., McMartin, C., Guida, W. C. (1996). The art and practice of structure-based drug design: a molecular modeling perspective. Medicinal Research Reviews, 16(1), 3-50.
111. Dictionary of Natural Products, Version 17.1 (2008) Chapmann & Hall/CRC Informa; http://www.crcpress.com/
112. Berdy, J. (2005). Bioactive microbial metabolites: a personal view. Journal of Antibiotics, 58(1), 1-26.
113. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research, 34(Database), D668-D672.
114. Oprea, T. I., Gottfries, J. (2001). Chemography: the art of navigating in chemical space. Journal of Combinatorial Chemistry, 3(2), 157-166.
115. Oprea, T. I., Gottfries, J., Sherbukhin, V., Svensson, P., Kuhler, T. C. (2000). Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces. Journal of Molecular Graphics and Modelling, 18(4/5), 512-524.
116. Oprea, T. I., Zamora, I., Ungell, A.-L. (2002). Pharmacokinetically based mapping device for chemical space navigation. Journal of Combinatorial Chemistry, 4(4), 258-266.
117. Larsson, J., Gottfries, J., Bohlin, L., Backlund, A. (2005). Expanding the ChemGPS chemical space with natural products. Journal of Natural Products, 68(7), 985-991.
118. Larsson, J., Gottfries, J., Muresan, S., Backlund, A. (2007). ChemGPS-NP: tuned for navigation in biologically relevant chemical space. Journal of Natural Products, 70(5), 789-794.
119. Koch, M. A., Schuffenhauer, A., Scheck, M., Wetzel, S., Casaulta, M., Odermatt, A., Ertl, P., Waldmann, H. (2005). Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proceedings of the National Academy of Sciences of the United States of America, 102(48), 17272-17277.
120. Schuffenhauer, A., Ertl, P., Roggo, S., Wetzel, S., Koch, M. A., Waldmann, H. (2007). The scaffold tree-visualization of the scaffold universe by hierarchical scaffold classification. Journal of Chemical Information and Modeling, 47(1), 47-58.
121. Burke, M. D., Schreiber, S. L. (2004). A planning strategy for diversity-oriented synthesis. Angewandte Chemie, International Edition, 43(1), 46-58.
122. Sadowski, J., Kubinyi, H. (1998). A scoring scheme for discriminating between drugs and nondrugs. Journal of Medicinal Chemistry, 41(18), 3325-3329.
123. Schreiber, S. L. (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery. Science, 287(5460), 1964-1969.
124. Shah, A. V., Walters, W. P., Murcko, M. A. (1998). Can we learn to distinguish between ''drug-like'' and ''nondrug-like'' molecules? Journal ofMedicinal Chemistry, 41(18), 3314-3324.
125. Walters, W. P., Ajay, Murcko, M. A. (1999). Recognizing molecules with drug-like properties. Current Opinion in Chemical Biology, 3(4), 384-387.
126. Anon (2007). A decade of drug-likeness. Nature Reviews Drug Discovery, 6(11), 853.
127. Hann, M. M., Leach, A. R., Burrows, J. N., Griffen, E. (2006). Lead discovery and the concepts of complexity and lead-likeness in the evolution of drug candidates. Comprehensive Medicinal Chemistry II, 4, 435-458.
128. Muresan, S., Sadowski, J. (2008). Properties guiding drug- and lead-likeness. Methods and Principles in Medicinal Chemistry, 37, 441-461.
129. Nettles, J. H., Jenkins, J. L., Bender, A., Deng, Z., Davies, J. W., Glick, M. (2006). Bridging chemical and biological space: ''Target Fishing'' using two- and threedimensionalmolecular descriptors. Journal of Medicinal Chemistry, 49(23), 6802-6810.
130. Oprea, T. I. (2005). Pursuing leadlikeness in pharmaceutical research. Joint Meeting on Medicinal Chemistry, Proceedings, Vienna, Austria, June 20-23, 1-4.
131. Rishton, G. M. (2002). Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today, 8(2), 86-96.
132. Rishton, G. M. (2008). Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. Current Opinion in Chemical Biology 12(3), 340-351.
133. Zhang, M.-Q., Wilkinson, B. (2007). Drug discovery beyond the 'rule-of-five'. Current Opinion in Biotechnology, 18(6), 478-488.
134. Breinbauer, R., Vetter, I. R., Waldmann, H. (2002). From protein domains to drug candidates: natural products as guiding principles in the design and synthesis of compound libraries. Angewandte Chemie, International Edition, 41(16), 2878-2890.
135. Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M., Freidinger, R. M., Whitter, W. L., Lundell, G. F., Veber, D. F., Anderson, P. S., et al. (1988). Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. Journal of Medicinal Chemistry, 31(12), 2235-2246
136. Mueller, G. (2003). Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today, 8(15), 681-691.
137. Koch, M. A., Wittenberg, L.-O., Basu, S., Jeyaraj, D. A., Gourzoulidou, E., Reinecke, K., Odermatt, A., Waldmann, H. (2004). Compound library development guided by protein structure similarity clustering and natural product structure. Proceedings of the National Academy of Sciences of the United States of America, 101(48), 16721-16726.
138. No ren-Mu ller, A., Reis-Correa, J. I., Prinz, H., Rosenbaum, G., Saxena, K., Schwalbe, H. J., Vestweber, D., Cagna, G., Schunk, S., Schwarz, O., Schiewe, H., Waldmann, H. (2006). Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 10606-10611.
139. Ertl, P. (2003). Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. Journal of Chemical Information and Computer Sciences, 43(2), 374-380.
140. Fink, T., Bruggesser, H., Reymond, J.-L. (2005). Virtual exploration of the smallmolecule chemical universe below 160 Da. Angewandte Chemie, International Edition, 44(10), 1504-1508.
141. Fink, T., Reymond, J.-L. (2007). Virtual exploration of the chemical universe up to atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. Journal of Chemical Information and Modeling, 47(2), 342-353.
142. Gorse, A.-D. (2006). Diversity in medicinal chemistry space. Current Topics in Medicinal Chemistry, 6(1), 3-18.
143. Schuerer, S. C., Tyagi, P., Muskal, S. M. (2005). Prospective exploration of synthetically feasible, medicinally relevant chemical space. Journal of Chemical Information and Modeling, 45(2), 239-248.
144. Kartal, M. (2007). Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytotherapy Research, 21, 113-119.
145. Boyd, M. R. (1996). The position of intellectual property rights in drug discovery and development from natural products. Journal of Ethnopharmacology, 51, 17-27.
146. Aguilar, G. (2001). Access to genetic resources and protection of traditional knowledge in the territories of indigenous peoples. Environmental Science and Policy, 4, 241-256.
147. Convention on Biological Diversity; http://www.cbd.int/ (29 August).
148. Kursar, T. A., Caballero-George, C. C., Capson, T. L., Cubilla-Rios, L., Gerwick, W. H., Gupta, M. R., Iban ez, A., Linington, R. G., Mcphail, K. L., Ortegabarria, E., Romero, L. I., Solis, P. N., Coley, P. D. (2006). Securing economic benefits and promoting conservation through bioprospecting. BioScience, 56, 1005-1012.
149. Kursar, T. A., Caballero-George, C. C., Capson, T. L., Cubilla-Rios, L., Gerwick, W. H., Keller, M. V., Iban ez, A., Linington, R. G., Mcphail, K. L., Ortegabarria, E., Romero, L. I., Coley, P. D. (2007). Linking bioprospecting with sustainable development and conservation: the Panama case. Biodiversity and Conservation, 16, 2789-2800.
150. Christoffersen, L. P., Mathur, E. J. (2005). Bioprospecting ethics and benefits A model for effective benefit-sharing. Industrial Biotechnology, 1, 255-259.
151. Vuorela, P., Leinonen, M., Saikku, P., Tammela, P., Rauha, J.-P., Wennberg, T., Vuorela, H. (2004). Natural products in the process of finding new drug candidates. Current Medicinal Chemistry, 11, 1375-1339.
152. Sarker, S. D., Latif, Z., Gray, A. I. (2005). Natural products isolation, 2nd edn, Vol. 20, Humana Press, Totowa, NJ.
153. Sarker, S. D., Nahar, L. (2005). Hyphenated techniques. In: Sarker, S. D., Latif, Z., Gray, A. I. eds. Natural products isolation, Vol. 20, pp. 233-267, Humana Press, Totowa, NJ.
154. Lang, G., Mayhudin, N. A., Mitova, M. I., Sun, L., van der Sar, S., Blunt, J. W., Cole, A. L. J., Ellis, G., Laatsch, H., Munro, M. H. G. (2008). Evolving trends in the dereplication of natural product extracts: new methodology for rapid, smallscale investigation of natural product extracts. Journal of Natural Products, 71, 1595-1599.
155. Gassner, N. C., Tamble, C. M., Bock, J. E., Cotton, N., White, K. N., Tenney, K., St. Onge, R. P., Proctor, M. J., Giaever, G., Nislow, C., Davis, R. W., Crews, P., Holman, T. R., Lokey, R. S. (2007). Accelerating the discovery of biologically active small molecules using a high-throughput yeast halo assay. Journal of Natural Products, 70, 383-390.
156. Kwon, S. J., Lee, M.-Y., Ku, B., Sherman, D. H., Dordick, J. S. (2007). Highthroughput, microarray-based synthesis of natural product analogues via in vitro metabolic pathway construction. ACS Chemical Biology, 2, 419-425.
157. Lokey, R. S. (2003). Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia. Current Opinion in Chemical Biology, 7(1), 91-96.
158. Walsh, D. P., Chang, Y. T. (2006). Chemical genetics. Chemical Reviews, 106(6), 2476-2530.
159. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., McPhail, A. T. (1971). Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus breoifolia. Journal of the American Chemical Society, 93, 2325-2327.
160. Leistner, E. (2005). Arzneimittel aus der natur die biologie der taxane. Pharmazie in Unserer Zeit, 34, 98-103.
161. Schiff, P. B., Fant, J., Horwitz, S. B. (1979). Promotion of microtubule assembly in vitro by Taxol. Nature, 277, 665-667.
162. Horwitz, S. B. (1992). Mechanism of action of Taxol. Trends in Pharmacological Sciences, 13, 132-136.
163. Cragg, G. M., Schepartz, S. A., Suffness, M., Grever, M. R. (1993). The Taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. Journal of Natural Products, 56, 1657-1668.
164. Holton, R. A., Somoza, C., Kim, H.-B., Liang, F., Biediger, R. J., Boatman, P. D., Shindo, M., Smith, C. C., Kim, S., Nadizadeh, H., Suzuki, Y., Tao, C., Vu, P., Tang, S., Zhang, P., Murthi, K. K., Gentile, L. N., Liu, J. H. (1994). First total synthesis of Taxol 1. Functionalization of the B ring. Journal of the American Chemical Society, 116, 1597-1598.
165. Holton, R. A., Kim, H.-B., Somoza, C., Liang, F., Biediger, R. J., Boatman, P. D., Shindo, M., Smith, C. C., Kim, S., Nadizadeh, H., Suzuki, Y., Tao, C., Vu, P., Tang, S., Zhang, P., Murthi, K. K., Gentile, L. N., Liu, J. H. (1994). First total synthesis of Taxol. 2. Completion of the C and D rings. Journal of the American Chemical Society, 116, 1599-1600.
166. Nicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Clairborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., Sorensen, E. J. (1994). Total synthesis of Taxol. Nature, 367, 630-634.
167. Danishefsky, S. J., Masters, J. J., Young, W. B., Link, J. T., Snyder, L. B., Magee, T. V., Jung, D. K., Isaacs, R. C. A., Bornmann, W. G., Alaimo, C. A., Coburn, C. A., Di Grand, M. J. (1996). Total synthesis of baccatin III and Taxol Journal of the American Chemical Society, 118, 2843-2859.
168. Wender, P. A., Badham, N. F., Conway, S. P., Floreancig, P. E., Glass, T. E., Houze, J. B., Krauss, N. E., Lee, D., Marquess, D. G., McGrane, P. L., Meng, W., Natchus, M. G., Shuker, A. J., Sutton, J. C., Taylor, R. E. (1997). The pinene path to taxanes. 6. A concise stereocontrolled synthesis of Taxol. Journal of the American Chemical Society, 119, 2757-2758.
169. Kusama, H., Hara, R., Kawahara, S., Nishimori, T., Kashima, H., Nakamura, N., Morihira, K., Kuwajima, I. (2000). Enantioselective total synthesis of (-)-Taxol. Journal of the American Chemical Society, 122, 3811-3820.
170. Mukaiyama, T., Shiina, I., Iwadare, H., Saitoh, M., Nishimura, T., Ohkawa, N., Sakoh, H., Nishimura, K., Tani, Y.-I., Hasegawa, M., Yamada, K., Saitoh, K. (1999). Asymmetric total synthesis of Taxol. Chemistry-A European Journal, 5, 121-161.
171. Denis, J. N., Green, A. E., Guenard, D., Gueritte-Voegelein, F., Mangatal, L., Potier, P. (1988). A highly efficient, practical approach to natural Taxol. Journal of the American Chemical Society, 110, 5517-5519.
172. Sisti, N. J., Swindell, C. S., Chander, M. C. (1996). Preparation of paclitaxel. 96- US10228 9640667, 19960607.
173. Sisti, N. J., Swindell, C. S., Chander, M. C. (1999). Paclitaxel synthesis from protected precursor compounds. 95-483082 5948919, 19950607.
174. Gibson, F. S. (2000). US 20006020507.
175. Agency, U. E. P. (2004). Greener synthetic pathways award; http://www.epa.gov/ greenchemistry/pubs/pgcc/winners/gspa04.html (29 August).
176. Gunasekera, S. P., Gunasekera, M., Longley, R. E., Schulte, G. K. (1990). Discodermolide-a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. Journal of Organic Chemistry, 55, 4912-4915.
177. Gunasekera, S. P., Gunasekera, M., Longley, R. E., Schulte, G. K. (1991). Discodermolide-a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta-correction. Journal of Organic Chemistry, 56, 1346.
178. Minguez, J. M., Kim, S. Y., Giuliano, K. A., Balachandran, R., Madiraju, C., Day, B. W., Curran, D. P. (2003). Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)discodermolide. Bioorganic and Medicinal Chemistry, 11(15), 3335-3357.
179. Smith, A. B., Beauchamp, T. J., LaMarche, M. J., Kaufmann, M. D., Qui, Y., Arimoto, H., Jones, D. R. (2000). Evolution of a gram-scale synthesis of (+) discodermolide. Journal of the American Chemical Society, 122, 8654-8664.
180. Smith, A. B., Kaufman, M. D., Beauchamp, T. J., LaMarche, M. J., Arimoto, H. (1999). Gram-scale synthesis of (+)discodermolide. Organic Letters, 1, 1823-1826.
181. Marshall, J. A., Johns, B. A. (1998). Total synthesis of (+)discodermolide. Journal of Organic Chemistry, 63, 7885-7892.
182. Paterson, I., Florence, G. J., Gerlach, K., Scott, J. P. (2000). Total synthesis of the antimicrotubule agent (+)discodermolide using boron-mediated aldol reactions of chiral ketones. Angewandte Chemie-International Edition, 39, 377-380.
183. Mickel, S. J., Sedelmeier, G. H., Niederer, D., Daeffler, R., Osmani, A., Schreiner, K., Seeger-Weibel, M., Berod, B., Schaer, K., Gamboni, R., Chen, S., Chen, W., Jagoe, C. T., Kinder, J. F. R., Loo, M., Prasad, K., Repic, O., Shieh, W.-C., Wang, R.-M., Waykole, L., Xu, D. D., Xue, S. (2004). Large-scale synthesis of the anticancer marine natural product (+)discodermolide. Part 1: synthetic strategy and preparation of a common precursor. Organic Process Research and Development, 4, 92-100.
184. Mickel, S. J., Sedelmeier, G. H., Niederer, D., Schuerch, F., Grimler, D., Koch, G., Daeffler, R., Osmani, A., Hirni, A., Schaer, K., Gamboni, R., Bach, A., Chaudhary, A., Chen, S., Chen, W., Hu, B., Jagoe, C. T., Kim, H.-Y., Kinder, J. F. R., Liu, Y., Lu, Y., McKenna, J., Prasad, K., Ramsey, T. M., Repic?, O., Rogers, L., Shieh, W.-C., Wang, R.-M., Waykole, L. (2004). Large-scale synthesis of the anti-cancer marine natural product (+)discodermolide. Part 2: synthesis of fragments C1-6 and C9-14. Organic Process Research and Development, 2, 101-106.
185. Mickel, S. J., Sedelmeier, G. H., Niederer, D., Schuerch, F., Koch, G., Kuesters, E., Daeffler, R., Osmani, A., Seeger-Weibel, M., Schmid, E., Hirni, A., Schaer, K., Gamboni, R., Bach, A., Chen, S., Chen, W., Geng, P., Jagoe, C. T., Kinder, J. F. R., Lee, G. T., McKenna, J., Ramsey, T. M., Repic?, O., Rogers, L., Shieh, W.-C., Wang, R.-M., Waykole, L. (2004). Large-scale synthesis of the anti-cancer marine natural product (+)discodermolide. Part 3: synthesis of fragment C15-21. Organic Process Research and Development, 8, 107-112.
186. Mickel, S. J., Sedelmeier, G. H., Niederer, D., Schuerch, F., Seger, M., Schreiner, K., Daeffler, R., Osmani, A., Bixel, D., Loiseleur, O., Cercus, J., Stettler, H., Schaer, K., Gamboni, R., Bach, A., Chen, G.-P., Chen, W., Geng, P., Lee, G. T., Loeser, E., McKenna, J., Kinder, J. F. R., Konigsberger, K., Prasad, K., Ramsey, T. M., Reel, N., Repic?, O., Rogers, L., Shieh, W.-C., Wang, R.-M., Waykole, L., Xue, S. (2004). Large-scale synthesis of the anti-cancer marine natural product (+)discodermolide. Part 4: preparation of fragment C7-24. Organic Process Research and Development, 8, 113-121.
187. Mickel, S. J., Niederer, D., Daeffler, R., Osmani, A., Kuesters, E., Schmid, E., Schaer, K., Gamboni, R., Chen, W., Loeser, E., Kinder, J. F. R., Konigsberger, K., Prasad, K., Ramsey, T. M., Repic, O., Wang, R.-M., Florence, G., Lyothier, I., Paterson, I. (2004). Large-scale synthesis of the anti-cancer marine natural product (+)discodermolide. Part 5: linkage of fragments C1-6 and C7-24 and finale. Organic Process Research and Development, 8, 122-130.
188. Mita, A., Lockhart, A. C., Chen, T.-L., Bochinski, K., Curtright, J., Cooper, W., Hammond, L., Rothenberg, M., Rowinsky, E., Sharma, S. (2004). A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every wks to adult patients with advanced solid malignancies. Journal of Clinical Oncology, 22(14S), 2025.
189. Breinbauer, R., Manger, M., Scheck, M., Waldmann, H. (2002). Natural product guided compound library development. Current Medicinal Chemistry, 9(23), 2129-2145.
190. Tan, D. S. (2005). Diversity-oriented synthesis: exploring intersections between chemistry and biology. Nature Chemical Biology, 1(2), 74-84.
191. Morton, D., Leach, S., Cordier, C., Warriner, S., Nelson, A. (2009). Synthesis of natural-product-like molecules with over eighty distinct scaffolds. Angewandte Chemie-International Edition, 48(1), 104-109.
192. No ren-Mu ller, A., Reis-Corre a, J. I., Prinz, H., Rosenbaum, C., Saxena, K., Schwalbe, H. J., Vestweber, D., Cagna, G., Schunk, S., Schwarz, O., Schiewe, H., Waldmann, H. (2006). Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 10606-10611.
193. Rosenbaum, C., Baumhof, P., Mazitschek, R., Mu ller, O., Giannis, A., Waldmann, H. (2004). Synthesis and biological evaluation of an indomethacin library revaels a new class of angiogenesis-related kinase inhibitors. Angewandte Chemie- International Edition, 43, 224-228.
194. Rosenbaum, C., Katzka, C., Marzinzik, A., Waldmann, H. (2003). Traceless Fischer indole synthesis on the solid phase. Chemical Communications, 1822-1823.
195. Barluenga, S., Wang, C., Fontaine, J. G., Aouadi, K., Beebe, K., Tsutsumi, S., Neckers, L., Winssinger, N. (2008). Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angewandte Chemie-International Edition, 47, 4432-4435.
196. Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., Sawyers, C. L. (2002). BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 100, 3041-3044.
197. Peng, C., Brain, J., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R., Read, M., Li, S. (2007). Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood, 110, 678-685.
198. Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., Rosen, N. (2003). Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Research, 63, 2139-2144.
199. Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N., Greengard, P., Chiosis, G. (2007). Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America, 104, 9511-9516.
200. Yang, Z.-Q., Geng, X., Solit, D., Pratilas, C. A., Rosen, N., Danishefsky, S. J. (2004). New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. Journal of the American Chemical Society, 126, 7881-7889.
201. Agatsuma, T., Ogawa, H., Akasaka, K., Asai, A., Yamashita, Y., Mizukami, T., Akinaga, S., Saitoh, Y. (2002). Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities Bioorganic and Medicinal Chemistry, 10, 3445-3454.
202. Waldmann, H., Khedkar, V., Du ckert, H., Schu rmann, S., Oppel, I. M., Kumar, K. (2008). Asymmetric synthesis of natural product inspired tricyclic benzopyrones by an organocatalyzed annulation reaction. Angewandte Chemie-International Edition, 47, 6869-6872.
203. Payne, D. J., Hueso-Rodriguez, J. A., Boyd, H., Concha, N. O., Janson, C. A., Gilpin, M., Bateson, J. H., Cheever, C., Niconovich, N. L., Pearson, S., Rittenhouse, S., Tew, D., Diez, E., Pe rez; de la Fuente, J., Rees, M., Rivera-Sagredo, A. (2002). Identification of a series of tricyclic natural products as potent broadspectrum inhibitors of metallo-b-lactamases. Antimicrobial Agents Chemotherapy, 46(6), 1880-1886.
204. Ley, S. V., Ladlow, M., Vickerstaffe, E. (2006). The use of polymer-assisted solution-phase synthesis and automation for the high-throughput preparation of biologically active compounds. Exploiting Chemical Diversity for Drug Discovery, 3-32.
205. Mentel, M., Breinbauer, R. (2007). Combinatorial solid-phase natural product chemistry. Topics in Current Chemistry, 278, 209-241.
206. Ley, S. V., Baxendale, I. R. (2002). New tools and concepts for modern organic synthesis. Nature Reviews Drug Discovery, 1(8), 573-586.
207. Ley, S. V., Baxendale, I. R. (2008). The changing face of organic synthesis. Chimia, 62(3), 162-168